ZINFORO®: Optimising outcomes for patients with CAP1-5,*
| Header | ||
|---|---|---|
| Header | Header | Header |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
| Content | Content | Content |
*There is no experience with ZINFORO® in the treatment of CAP in the following patient groups: The immunocompromised, patients with severe sepsis/septic shock, severe underlying lung disease; patients with PORT risk Class V, and/or CAP requiring ventilation at presentation, CAP due to MRSA; and patients requiring intensive care. The available clinical data cannot substantiate efficacy against PNSP. Caution is advised when treating such patients.1
†Potency has been demonstrated in clinical studies of CAP against pathogens that were susceptible to antibiotics in vitro. In vitro activity does not always correlate with clinical efficacy.
CAP, community-acquired pneumonia; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; PNSP, penicillin non-susceptible Streptococcus pneumoniae; PORT, Pneumonia Patient Outcomes Research Team.
References:
Please click the Prescribing Information link to view the safety and adverse events information of ZINFORO®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-ZFO-IND-0417 June 2022
Example
Example
Fifth-generation cephalosporin with broad coverage
Simple dosing with a flexible infusion time
Safety profile consistent with other cephalosporins
ZINFORO® in the treatment of CAP and cSSTI
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Hac habitasse platea dictumst quisque sagittis purus sit amet volutpat. Lectus magna fringilla urna porttitor rhoncus. Venenatis urna cursus eget nunc scelerisque viverra. Id donec ultrices tincidunt arcu non sodales.
Sagittis aliquam malesuada bibendum arcu vitae elementum curabitur. Pellentesque elit ullamcorper dignissim cras tincidunt. Orci ac auctor augue mauris augue neque. Dui vivamus arcu felis bibendum ut tristique et egestas quis. Sed vulputate mi sit amet mauris commodo.
Nunc eget lorem dolor sed viverra ipsum. Sed ullamcorper morbi tincidunt ornare.
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered Medical Practitioner*, please visit
https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 13th September 2019.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.